Investor, I don't know if anyone in Abbott upper management really has a good grasp on the value of the RECAF test. As to profits, dollar for dollar, the drug side returns much more money than the diagnostic side and the 8.3 billion figure was really high. Also, since Abbott diagnostic has a lot of management problems, other decision could be suspect also.
This test is going to be huge, probalby more that the head people at Abbott realize. If you look at it on the surface, it is just a cancer test that does not even tell you where the cancer is. That is enough to raise eyebrows at the value of the test. What they may not have connected yet is the type of test involved. RECAF tests for the receptor that passes sugars to the cancer cells. IMO, altered sugar therapy is going to be huge. There are five groups that I know of working on that method of therapy. I have always suspected RECAF was involved in the process and one company recently even spelled it out. They are using the "receptor for AFP" to deliver the drug.
Since RECAF is testing for the exact method of treatment, the correlation would be 100%. If the sugar therapy becomes as good as I think it will, the demand for RECAF will be huge. I have not approached this casually as I have dug as deeply into this investment as possible. I am sold and believe me, I am a tough sell.
News 
Market Data 
Discover 
